nach oben

World Journal of Urology

Erschienen in:

29.10.2018 | Topic Paper

PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics

verfasst von: R. S. Eapen, T. C. Nzenza, D. G. Murphy, M. S. Hofman, M. Cooperberg, N. Lawrentschuk

Erschienen in: World Journal of Urology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

The heterogeneity of prostate cancer has made imaging modalities of crucial importance in this disease. Accurate diagnosis and staging of the volume and extent of disease, especially in advanced and metastatic prostate cancer, can help to tailor the timing and modalities of treatment. While MRI has been effective in the detection of significant prostate cancer, its use in the identification and quantification of extraprostatic disease is limited. This gap is now being filled by PSMA PET. PSMA PET scans have now been shown to have a role in all stages in the prostate cancer journey. Emerging evidence has shown its promise in primary staging, restaging and theranostics. In this paper, we review the evidence for the use of PSMA PET in the various stages of prostate cancer, from initial diagnosis to advanced metastatic disease where other systemic treatments have failed.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMed

Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D et al (2001) Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol Austria. Urology 58:417–424CrossRefPubMed

Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14:15–25CrossRefPubMed

Toner L, Papa N, Perera M, Katelaris N, Weerakoon M, Chin K et al (2017) Multiparametric magnetic resonance imaging for prostate cancer—a comparative study including radical prostatectomy specimens. World J Urol 35:935–941CrossRefPubMed

Calopedos RJS, Chalasani V, Asher R, Emmett L, Woo HH (2017) Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20:352–360CrossRefPubMed

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T et al (2018) [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 19:825–833CrossRefPubMed

Silver DA, Pellicer I, Fair WR, Heston WDW, CordonCardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMed

DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI (2003) Pathological and molecular aspects of prostate cancer. Lancet 361:955–964CrossRefPubMed

Sweat SD, Pacelli A, Murphy GP, Bostwick DG (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640CrossRefPubMed

10.

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261CrossRefPubMed

11.

Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH et al (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 108:9578–9582CrossRefPubMedPubMedCentral

12.

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20CrossRefPubMed

13.

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (2018) Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the us preventive services task force. JAMA 319:1914–1931CrossRefPubMed

14.

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822CrossRefPubMed

15.

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. New Engl J Med 378:1767–1777CrossRefPubMed

16.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I et al (2016) Simultaneous (68)Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70:829–836CrossRefPubMed

17.

Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM et al (2018) (68)Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol 200:95–103CrossRefPubMed

18.

Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395CrossRefPubMed

19.

Corfield J, Perera M, Bolton D, Lawrentschuk N (2018) (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 36:519–527CrossRefPubMed

20.

Hofman MS, Hicks RJ, Maurer T, Eiber M (2018) Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 38:200–217CrossRefPubMed

21.

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q et al (2017) Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 119:209–215CrossRefPubMed

22.

Isabel R, Charlotte D, Martina W, Margret S, Hans-Jürgen W, Kristina S et al (2017) Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int 120:40–47CrossRef

23.

Geurts N, Lamb AD, Lawrentschuk N, Murphy DG (2017) Prostate-specific membrane antigen radioguided surgery: a promising utility. BJU Int 120:5–6CrossRefPubMed

24.

Murphy DG, Hofman M, Lawrentschuk N, Maurer T (2017) Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer. BJU Int 119:194–195CrossRefPubMed

25.

Hofman, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA et al (2018) A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. https://doi.org/10.1111/bju.14374 [Epub ahead of print] CrossRefPubMed

26.

Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C et al (2016) Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res 6:78CrossRefPubMedPubMedCentral

27.

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRefPubMed

28.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G (2016) (68)Ga-Labeled Prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. https://doi.org/10.1016/j.euf.2016.11.002 CrossRef

29.

Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74:179–190CrossRefPubMed

30.

van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B et al (2016) (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117:732–739CrossRefPubMed

31.

Hicks RJ, Murphy DG, Williams SG (2017) Seduction by sensitivity: reality, illusion, or delusion? The challenge of assessing outcomes after PSMA imaging selection of patients for treatment. J Nucl Med 58:1969–1971CrossRefPubMed

32.

EAU (2018) EAU guidelines 2018 edition. Prostate cancer. EAU, Arnhem, p 2018

33.

Clarebrough E, Duncan C, Christidis D, Lavoipierre A, Lawrentschuk N (2018) PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach. World J Urol. https://doi.org/10.1007/s00345-018-2282-y CrossRefPubMed

34.

Murphy DG, Sweeney CJ, Tombal B (2017) “Gotta catch ‘em all”, or do we? Pokemet approach to metastatic prostate cancer. Eur Urol 72:1–3CrossRefPubMed

35.

Nair R, Lamb BW, Geurts N, Alghazo O, Lam W, Lawrentschuk N et al (2017) The role of local therapy for oligometastatic prostate cancer: should we expect a cure? Urol Clin N Am 44:623–633CrossRef

36.

Hertz BE, Schuller KE (2010) Saul Hertz, MD (1905–1950): a pioneer in the use of radioactive iodine. Endocr Pract 16:713–715CrossRefPubMed

37.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90CrossRefPubMed

38.

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A et al (2017) (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 44:81–91CrossRefPubMed

39.

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E et al (2015) Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5:114PubMed

40.

Fendler WP, Reinhardt S, Ilhan H, Delker A, Boning G, Gildehaus FJ et al (2017) Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget 8:3581–3590CrossRefPubMed

41.

Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A et al (2016) PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med 57:1170–1176CrossRefPubMed

42.

Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T et al (2016) Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol 196:382–391CrossRefPubMed

43.

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S et al (2016) 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med 57:1006–1013CrossRefPubMed

44.

Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y et al (2016) PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med 57:97s–104sCrossRefPubMed

45.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154CrossRefPubMed

Titel: PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics
verfasst von: R. S. Eapen
T. C. Nzenza
D. G. Murphy
M. S. Hofman
M. Cooperberg
N. Lawrentschuk
Publikationsdatum: 29.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 7/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2524-z

Neu im Fachgebiet Urologie

10.04.2024 | PSA-Screening | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics

Abstract

Neu im Fachgebiet Urologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

TURP hat Vorteile im Vergleich mit der Embolisation

Langes Sitzen in der Freizeit korreliert mit erektiler Dysfunktion

Update Urologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract

Versatile algorithmic midline approach to perineal urethrostomy for complex urethral strictures

PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach

The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis

Photoselective vaporization has comparative efficacy and safety among high-risk benign prostate hyperplasia patients on or off systematic anticoagulation: a meta-analysis

The effect of short-term preoperative ureteral stenting on the outcomes of retrograde intrarenal surgery for renal stones

Neu im Fachgebiet Urologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Wie toxische Männlichkeit der Gesundheit von Männern schadet

TURP hat Vorteile im Vergleich mit der Embolisation

Langes Sitzen in der Freizeit korreliert mit erektiler Dysfunktion

Update Urologie